Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HUMANA INCHUM · Entity 1429 | Director | January 02, 2026 | January 05, 2026 |
| Hewlett Packard Enterprise CoHPE · Entity 2984 | Director | May 01, 2026 | May 05, 2026 |
| PFIZER INCPFE · Entity 2863 | Executive Vice President | February 26, 2022 | March 01, 2022 |
| Viatris IncVTRS · Entity 3277 | Director | March 06, 2026 | March 10, 2026 |
| Zoetis Inc.ZTS · Entity 679 | Director | August 07, 2026 | August 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HUMANA INC
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 26,826 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 766 · Balance 26,826 F1: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a I-for-I basis, exempt pursuant to Rule 16(b)-3(d)(I). Includes 766 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule I 6b-3(d)(I )&(3) under the Company's 2019 Amended & Restated Plan. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,467 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 2,467 F2: Director's cash fee elected to be converted into stock units, deferred at the election of the reporting person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis (over a five-year period), exempt pursuant to Rule 16(b)-3(d)(1). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 318 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 318 F3: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). |
| Humana CommonSEC Table I · non-derivative | IndirectSee Footnote | 20,634 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 20,634 F4: Transferred 20,634 shares into new 2024 Grantor Retained Annuity Trust effective 4/29/24, where reporting person is the sole Trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a I-for-I basis, exempt pursuant to Rule 16(b)-3(d)(I). Includes 766 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule I 6b-3(d)(I )&(3) under the Company's 2019 Amended & Restated Plan.
F2: Director's cash fee elected to be converted into stock units, deferred at the election of the reporting person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis (over a five-year period), exempt pursuant to Rule 16(b)-3(d)(1).
F3: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).
F4: Transferred 20,634 shares into new 2024 Grantor Retained Annuity Trust effective 4/29/24, where reporting person is the sole Trustee.
Hewlett Packard Enterprise Co
Report date May 01, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,750 |
Reported balance
After 2026-05-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-01 · Grant · Acquired 8,750 · Balance 8,750 F3: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4: On 05/01/26, the reporting person was granted 8,750 restricted stock units ("RSUs"), all of which will cliff vest on the earlier of 05/01/27 or the date of Issuer's 2027 Annual Stockholders Meeting. Dividend equivalent rights accrue with respect to these RSUs when and as dividends are paid on Issuer's common stock. The reporting person elected to defer the receipt of common stock until the termination of his service as a member of the Issuer's Board of Directors. |
| Common StockSEC Table I · non-derivative | Direct | 3,444 |
Reported balance
Holding disclosure · report date 2026-05-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 3,444 |
| Common StockSEC Table I · non-derivative | IndirectBy Merrill Lynch | 47,721.7622 |
Reported balance
Holding disclosure · report date 2026-05-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 47,721.7622 F1: The reporting person elected to defer the receipt of common stock until the termination of his service as a member of the Issuer's Board of Directors. F2: The number of shares in column 5 includes 144.4031 vested restricted stock unit ("RSU") dividend equivalent rights at $27.93 per RSU credited to the reporting person's account on 04/23/26. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person elected to defer the receipt of common stock until the termination of his service as a member of the Issuer's Board of Directors.
F2: The number of shares in column 5 includes 144.4031 vested restricted stock unit ("RSU") dividend equivalent rights at $27.93 per RSU credited to the reporting person's account on 04/23/26.
F3: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F4: On 05/01/26, the reporting person was granted 8,750 restricted stock units ("RSUs"), all of which will cliff vest on the earlier of 05/01/27 or the date of Issuer's 2027 Annual Stockholders Meeting. Dividend equivalent rights accrue with respect to these RSUs when and as dividends are paid on Issuer's common stock. The reporting person elected to defer the receipt of common stock until the termination of his service as a member of the Issuer's Board of Directors.
PFIZER INC
Report date February 26, 2022 · Filed March 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 555,941 |
Ending reported balance
After 2022-02-26 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-02-26 · Exercise / conversion · Acquired 127,160 · Balance 649,918 F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Row 2 · 2022-02-26 · Tax withholding · Disposed 34,607 · Balance 615,311 F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3: Price is the closing price of Pfizer common stock on February 25, 2022. Row 3 · 2022-02-26 · Tax withholding · Disposed 59,370 · Balance 555,941 F4: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $25.60 · Expires 2022-02-26 | Direct | 0 |
Reported balance
After 2022-02-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-02-26 · Exercise / conversion · Disposed 127,160 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F3: Price is the closing price of Pfizer common stock on February 25, 2022.
F4: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F5: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
Viatris Inc
Report date March 06, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,031 |
Ending reported balance
After 2026-03-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-06 · Exercise / conversion · Acquired 25,112 · Balance 25,112 Row 2 · 2026-03-06 · Exercise / conversion · Acquired 919 · Balance 26,031 F1: Fractional shares have been rounded up in connection with the settlement described in footnote 3 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-06 · Exercise / conversion · Disposed 25,112 · Balance 0 F2: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 15,890 |
Reported balance
After 2026-03-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-06 · Grant · Acquired 15,890 · Balance 15,890 F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027. |
| Dividend Equivalent UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-06 · Exercise / conversion · Disposed 918.455 · Balance 0 F3: Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on May 12, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. |
Filing footnotes · ownership attribution and instrument terms
F1: Fractional shares have been rounded up in connection with the settlement described in footnote 3 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan.
F2: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026.
F3: Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on May 12, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11.
F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027.
Zoetis Inc.
Report date August 07, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,808 |
Reported balance
After 2026-08-07 transaction · row 1
1 source rowRow 1 · 2026-08-07 · Gift · Disposed 6,650 · Balance 14,808 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 6,650 |
Reported balance
Holding disclosure · report date 2026-08-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,650 F1: Reflects a transfer by the Reporting Person of 6,650 shares to the Frank A. D'Amelio 2-Year 2026 GRAT No. 3. F2: Shares held in the Frank A. D'Amelio 2-Year 2026 GRAT No. 3, to which the reporting person is a grantor, trustee and beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a transfer by the Reporting Person of 6,650 shares to the Frank A. D'Amelio 2-Year 2026 GRAT No. 3.
F2: Shares held in the Frank A. D'Amelio 2-Year 2026 GRAT No. 3, to which the reporting person is a grantor, trustee and beneficiary.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Catalent, Inc.
Report date December 18, 2024 · Filed December 18, 2024
Section 16 reporting ended · disclosed 2024-12-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-12-18 transaction · row 1
1 source rowRow 1 · 2024-12-18 · Disposition to issuer · Disposed 12,635 · Balance 0 F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F2: Includes restricted stock units ("RSUs"). F3: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $63.50 in cash, without interest (the "Merger Consideration"). F4: At the Effective Time, each RSU, whether or not vested, outstanding immediately prior to the Effective Time vested (if unvested) and was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the RSU multiplied by (ii) the Merger Consideration, except for certain RSUs granted following the date of the Merger Agreement which were converted at the Effective Time into restricted cash awards equal to the product of (a) the Merger Consideration multiplied by (b) the number of shares of Issuer common stock subject to such award and otherwise remain subject to their terms, including vesting and acceleration terms. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger").
F2: Includes restricted stock units ("RSUs").
F3: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $63.50 in cash, without interest (the "Merger Consideration").
F4: At the Effective Time, each RSU, whether or not vested, outstanding immediately prior to the Effective Time vested (if unvested) and was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the RSU multiplied by (ii) the Merger Consideration, except for certain RSUs granted following the date of the Merger Agreement which were converted at the Effective Time into restricted cash awards equal to the product of (a) the Merger Consideration multiplied by (b) the number of shares of Issuer common stock subject to such award and otherwise remain subject to their terms, including vesting and acceleration terms.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2022 Filed Feb 25, 2022 23:04 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 126,794 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003466 · doc4.xml · derivative · entry 5 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,794 Underlying: Common Stock · 126,794 shares Expires 2027-02-24 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 23:04 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionStock Appreciation Rights · Derivative | 153,789 | $0.00 Strike: $27.34 | $0.00 |
DisclosureSEC source: 0001225208-22-003466 · doc4.xml · derivative · entry 4 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 153,789 shares Expires 2022-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 23:04 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 76,120 | $51.28 | $3,903,433.60 |
DisclosureSEC source: 0001225208-22-003466 · doc4.xml · nonDerivative · entry 3 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522,758 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 23:04 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 38,099 | $46.87 | $1,785,700.13 |
DisclosureSEC source: 0001225208-22-003466 · doc4.xml · nonDerivative · entry 2 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 598,878 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 23:04 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionCommon Stock | 153,789 | $27.34 | $4,204,591.26 |
DisclosureSEC source: 0001225208-22-003466 · doc4.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 12, 2022 Filed Feb 16, 2022 00:54 UTC | Zoetis Inc. ZTS · Entity 679 | GrantDeferred Stock Unit · Derivative | 2,673.1237 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001555280-22-000097 · wf-form4_164497282638568.xml · derivative · entry 2 DAMELIO FRANK A · CIK 0001194004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,673.1237 Underlying: Common Stock · 2,673.1237 shares Expires not disclosed F3 · security: Represents deferred stock units granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each a "DSU" and collectively, "DSUs"). The DSUs were fully vested on the date of the grant and will be settled in shares of Zoetis Inc. common stock upon the reporting person's separation from service as a director at Zoetis. F4 · derivative.exercise_price: Each DSU represents the right to receive one share of Zoetis Inc. common stock in accordance with the terms of the Zoetis Equity Deferral Plan. F5 · price: Upon the vesting of the reporting person's restricted stock units on 2/12/2022, the reporting person received 2,673.1237 deferred stock units ("DSUs") pursuant to a voluntary deferral under the Zoetis Inc. Amended and Restated Non-Employee Director Deferred Compensation Plan. The DSUs are fully vested and will be will be paid in a single lump payment within 30 business days following the earlier to occur of (i) a Termination Event, and (ii) a Change in Control that constitutes a "change in ownership or control" for purposes of Section 409A in accordance with the terms of the Plan. F5 · derivative.exercise_date: Upon the vesting of the reporting person's restricted stock units on 2/12/2022, the reporting person received 2,673.1237 deferred stock units ("DSUs") pursuant to a voluntary deferral under the Zoetis Inc. Amended and Restated Non-Employee Director Deferred Compensation Plan. The DSUs are fully vested and will be will be paid in a single lump payment within 30 business days following the earlier to occur of (i) a Termination Event, and (ii) a Change in Control that constitutes a "change in ownership or control" for purposes of Section 409A in accordance with the terms of the Plan. F5 · derivative.expiration_date: Upon the vesting of the reporting person's restricted stock units on 2/12/2022, the reporting person received 2,673.1237 deferred stock units ("DSUs") pursuant to a voluntary deferral under the Zoetis Inc. Amended and Restated Non-Employee Director Deferred Compensation Plan. The DSUs are fully vested and will be will be paid in a single lump payment within 30 business days following the earlier to occur of (i) a Termination Event, and (ii) a Change in Control that constitutes a "change in ownership or control" for purposes of Section 409A in accordance with the terms of the Plan. Read SEC document |
| February 12, 2022 Filed Feb 16, 2022 00:54 UTC | Zoetis Inc. ZTS · Entity 679 | Exercise / conversionRestricted Stock Unit · Derivative | 2,673.1237 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001555280-22-000097 · wf-form4_164497282638568.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,244.8149 Underlying: Common Stock · 2,673.1237 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 1,613.9322 RSUs will vest on February 11, 2023; 1,438.8827 RSUs will vest on February 10, 2024; and 1,192 RSUs will vest on February 8, 2025. F2 · derivative.exercise_price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F2 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F1 · derivative.exercise_date: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 1,613.9322 RSUs will vest on February 11, 2023; 1,438.8827 RSUs will vest on February 10, 2024; and 1,192 RSUs will vest on February 8, 2025. F1 · derivative.expiration_date: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 1,613.9322 RSUs will vest on February 11, 2023; 1,438.8827 RSUs will vest on February 10, 2024; and 1,192 RSUs will vest on February 8, 2025. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 23:35 UTC | Zoetis Inc. ZTS · Entity 679 | GrantRestricted Stock Unit · Derivative | 1,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001555280-22-000051 · wf-form4_164453611536773.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,917.9386 Underlying: Common Stock · 1,192 shares Expires not disclosed F1 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). Restricted stock units vest and are settled in shares of Zoetis common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. Dividend equivalent units vest and are settled in shares of Zoetis common stock on the third anniversary of the date of grant of the underlying restricted stock units, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F3 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. F4 · derivative.expiration_date: Not applicable. F5 · balance_after: The RSUs vest as follows: 2,673.1237 RSUs will vest on February 12, 2022; 1,613.9322 RSUs will vest on February 11, 2023; 1,438.8827 RSUs will vest on February 10, 2024; and 1,192 RSUs will vest on February 8, 2025. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 14:45 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 412 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-000510 · form4.xml · derivative · entry 8 DAMELIO FRANK A · CIK 0001194004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412 Underlying: Humana Common · 412 shares Expires not disclosed F4 · security: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/22. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/22. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/22. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/22. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:35 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionStock Appreciation Rights · Derivative | 152,785 | $0.00 Strike: $22.35 | $0.00 |
DisclosureSEC source: 0001225208-21-004302 · doc4.xml · derivative · entry 4 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 152,785 shares Expires 2021-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:35 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 96,872 | $34.64 | $3,355,646.08 |
DisclosureSEC source: 0001225208-21-004302 · doc4.xml · nonDerivative · entry 3 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483,188 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:35 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 27,381 | $33.49 | $916,989.69 |
DisclosureSEC source: 0001225208-21-004302 · doc4.xml · nonDerivative · entry 2 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,060 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 26, 2021. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:35 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionCommon Stock | 152,785 | $22.35 | $3,414,744.75 |
DisclosureSEC source: 0001225208-21-004302 · doc4.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 607,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 182,050 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004033 · doc4.xml · derivative · entry 6 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,050 Underlying: Common Stock · 182,050 shares Expires 2028-02-25 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 210,697 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004033 · doc4.xml · derivative · entry 5 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,697 Underlying: Common Stock · 210,697 shares Expires 2026-02-25 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionStock Appreciation Rights · Derivative | 163,334 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001225208-21-004033 · doc4.xml · derivative · entry 4 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 163,334 shares Expires 2021-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 105,707 | $34.76 | $3,674,375.32 |
DisclosureSEC source: 0001225208-21-004033 · doc4.xml · nonDerivative · entry 3 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,656 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 28,221 | $33.82 | $954,434.22 |
DisclosureSEC source: 0001225208-21-004033 · doc4.xml · nonDerivative · entry 2 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560,363 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionCommon Stock | 163,334 | $22.89 | $3,738,715.26 |
DisclosureSEC source: 0001225208-21-004033 · doc4.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 13, 2021 Filed Feb 17, 2021 22:18 UTC | Zoetis Inc. ZTS · Entity 679 | Exercise / conversionRestricted Stock Unit · Derivative | 2,779.1458 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001555280-21-000121 · wf-form4_161360026953953.xml · derivative · entry 3 DAMELIO FRANK A · CIK 0001194004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,694.57 Underlying: Common Stock · 2,779.1458 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 2,779.1458 RSUs vested on February 13, 2021; 2,658.4794 RSUs will vest on February 12, 2022; 1,605.0906 RSUs will vest on February 11, 2023; and 1,431 RSUs will vest on February 10, 2024. F1 · derivative.exercise_price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F3 · derivative.exercise_date: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 2,779.1458 RSUs vested on February 13, 2021; 2,658.4794 RSUs will vest on February 12, 2022; 1,605.0906 RSUs will vest on February 11, 2023; and 1,431 RSUs will vest on February 10, 2024. F3 · derivative.expiration_date: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 2,779.1458 RSUs vested on February 13, 2021; 2,658.4794 RSUs will vest on February 12, 2022; 1,605.0906 RSUs will vest on February 11, 2023; and 1,431 RSUs will vest on February 10, 2024. Read SEC document |
| February 13, 2021 Filed Feb 17, 2021 22:18 UTC | Zoetis Inc. ZTS · Entity 679 | OtherCommon Stock | 887 | $166.71 | $147,871.77 |
DisclosureSEC source: 0001555280-21-000121 · wf-form4_161360026953953.xml · nonDerivative · entry 2 DAMELIO FRANK A · CIK 0001194004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,808 F2 · kind: Disposition of shares to the Company in exchange for cash based on the closing share price of Zoetis Inc. common stock as of the vesting date. Read SEC document |
| February 13, 2021 Filed Feb 17, 2021 22:18 UTC | Zoetis Inc. ZTS · Entity 679 | Exercise / conversionCommon Stock | 2,779 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001555280-21-000121 · wf-form4_161360026953953.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:49 UTC | Zoetis Inc. ZTS · Entity 679 | GrantRestricted Stock Unit · Derivative | 1,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001555280-21-000072 · wf-form4_161317012277154.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,473.7158 Underlying: Common Stock · 1,431 shares Expires not disclosed F1 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). Restricted stock units vest and are settled in shares of Zoetis common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. Dividend equivalent units vest and are settled in shares of Zoetis common stock on the third anniversary of the date of grant of the underlying restricted stock units, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F3 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. F4 · derivative.expiration_date: Not applicable. F5 · balance_after: The RSUs vest as follows: 2,779.1458 RSUs will vest on February 13, 2021; 2,658.4794 RSUs will vest on February 12, 2022; 1,605.0906 RSUs will vest on February 11, 2023; and 1,431 RSUs will vest on February 10, 2024. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:15 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 403 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-21-000014 · edgar.xml · derivative · entry 7 DAMELIO FRANK A · CIK 0001194004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403 Underlying: Humana Common · 403 shares Expires not disclosed F5 · security: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/21. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/21. F5 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/21. F5 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/21. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:49 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionStock Appreciation Rights · Derivative | 173,675 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-20-004020 · doc4.xml · derivative · entry 4 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 173,675 shares Expires 2020-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:49 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 89,721 | $36.45 | $3,270,330.45 |
DisclosureSEC source: 0001225208-20-004020 · doc4.xml · nonDerivative · entry 3 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,250 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:49 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 41,113 | $33.42 | $1,373,996.46 |
DisclosureSEC source: 0001225208-20-004020 · doc4.xml · nonDerivative · entry 2 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,971 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:49 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionCommon Stock | 173,675 | $27.37 | $4,753,484.75 |
DisclosureSEC source: 0001225208-20-004020 · doc4.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:19 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 218,953 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003785 · doc4.xml · derivative · entry 8 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,953 Underlying: Common Stock · 218,953 shares Expires 2027-02-27 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:19 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 255,553 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003785 · doc4.xml · derivative · entry 7 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,553 Underlying: Common Stock · 255,553 shares Expires 2025-02-27 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:19 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionStock Appreciation Rights · Derivative | 144,928 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-20-003785 · doc4.xml · derivative · entry 6 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 144,928 shares Expires 2020-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:19 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 110,626 | $36.80 | $4,071,036.80 |
DisclosureSEC source: 0001225208-20-003785 · doc4.xml · nonDerivative · entry 5 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,409 F5 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F6 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:19 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 22,314 | $34.72 | $774,742.08 |
DisclosureSEC source: 0001225208-20-003785 · doc4.xml · nonDerivative · entry 4 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 493,035 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:19 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 12,537 | $34.72 | $435,284.64 |
DisclosureSEC source: 0001225208-20-003785 · doc4.xml · nonDerivative · entry 3 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 515,349 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:19 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 45,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003785 · doc4.xml · nonDerivative · entry 2 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 527,886 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:19 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionCommon Stock | 144,928 | $34.59 | $5,013,059.52 |
DisclosureSEC source: 0001225208-20-003785 · doc4.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 482,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 22:26 UTC | Zoetis Inc. ZTS · Entity 679 | Exercise / conversionRestricted Stock Unit · Derivative | 3,704.6976 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001555280-20-000117 · wf-form4_158215115996538.xml · derivative · entry 3 DAMELIO FRANK A · CIK 0001194004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,002.8287 Underlying: Common Stock · 3,704.6976 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 3,704.6976 RSUs vested on February 14, 2020; 2,763.4058 RSUs will vest on February 13, 2021; 2,643.4229 RSUs will vest on February 12, 2022; and 1,596 RSUs will vest on February 11, 2023. F1 · derivative.exercise_price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F3 · derivative.exercise_date: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 3,704.6976 RSUs vested on February 14, 2020; 2,763.4058 RSUs will vest on February 13, 2021; 2,643.4229 RSUs will vest on February 12, 2022; and 1,596 RSUs will vest on February 11, 2023. F3 · derivative.expiration_date: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 3,704.6976 RSUs vested on February 14, 2020; 2,763.4058 RSUs will vest on February 13, 2021; 2,643.4229 RSUs will vest on February 12, 2022; and 1,596 RSUs will vest on February 11, 2023. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 22:26 UTC | Zoetis Inc. ZTS · Entity 679 | OtherCommon Stock | 1,182 | $144.17 | $170,408.94 |
DisclosureSEC source: 0001555280-20-000117 · wf-form4_158215115996538.xml · nonDerivative · entry 2 DAMELIO FRANK A · CIK 0001194004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,916 F2 · kind: Disposition of shares to the Company in exchange for cash based on the closing share price of Zoetis Inc. common stock as of the vesting date. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 22:26 UTC | Zoetis Inc. ZTS · Entity 679 | Exercise / conversionCommon Stock | 3,704 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001555280-20-000117 · wf-form4_158215115996538.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 21:30 UTC | Zoetis Inc. ZTS · Entity 679 | GrantRestricted Stock Unit · Derivative | 1,596 | $0.00 | $0.00 |
DisclosureSEC source: 0001555280-20-000056 · wf-form4_158162941364405.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,707.5263 Underlying: Common Stock · 1,596 shares Expires not disclosed F1 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (collectively, "RSUs"). Restricted stock units vest and are settled in shares of Zoetis common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. Dividend equivalent units vest and are settled in shares of Zoetis common stock on the third anniversary of the date of grant of the underlying restricted stock units, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F3 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. F4 · derivative.expiration_date: Not applicable. F5 · balance_after: The RSUs vest as follows: 3,704.6976 RSUs will vest on February 14, 2020; 2,763.4058 RSUs will vest on February 13, 2021; 2,643.4229 RSUs will vest on February 12, 2022; and 1,596 RSUs will vest on February 11, 2023. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 16:49 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 453 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-20-000003 · edgar.xml · derivative · entry 7 DAMELIO FRANK A · CIK 0001194004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453 Underlying: Humana Common · 453 shares Expires not disclosed F5 · security: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/20. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/20. F5 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/20. F5 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/20. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 19,167 | $44.10 | $845,264.70 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 20 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,392 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 18,036 | $44.11 | $795,567.96 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 19 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,559 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 13,848 | $44.05 | $610,004.40 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 18 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,595 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 13,138 | $44.09 | $579,254.42 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 17 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,443 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 10,957 | $44.00 | $482,108.00 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 16 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,581 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 9,362 | $44.06 | $412,489.72 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 15 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,538 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 8,159 | $44.15 | $360,219.85 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 14 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,900 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 7,787 | $44.07 | $343,173.09 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 13 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,059 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 7,588 | $44.01 | $333,947.88 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 12 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,846 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.